Simufilam’s Phase 3 Alzheimer’s Trial Falls Short: Key End Points Unmet in Latest Study
“`html Cassava Sciences Halts Alzheimer’s Program After Simufilam Fails in Phase 3 Trials World-Today-News.com | March 26, 2025 – Cassava Sciences has officially ended its development program for simufilam, an experimental drug aimed at treating Alzheimer’s disease, following disappointing results from its Phase 3 clinical trials. Teh decision marks a significant setback in the search … Read more